Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANGIODYNAMICS INCANGO · Entity 5275 | Director | July 15, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANGIODYNAMICS INC
Report date July 15, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,322 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 11,887 · Balance 102,322 F1: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SI-BONE, Inc.
Report date June 25, 2021 · Filed June 28, 2021
Section 16 reporting ended · disclosed 2021-06-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,797 |
Ending reported balance
After 2021-06-25 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-06-25 · Exercise / conversion · Acquired 10,297 · Balance 19,094 Row 2 · 2021-06-25 · Exercise / conversion · Acquired 11,111 · Balance 30,205 Row 3 · 2021-06-25 · Sale · Disposed 11,111 · Balance 19,094 F1: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $33.19 to $33.57, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnotes. Row 4 · 2021-06-25 · Sale · Disposed 10,297 · Balance 8,797 F2: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $33.29 to $33.78, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnotes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.32 · Expires 2025-08-18 | Direct | 0 |
Reported balance
After 2021-06-25 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-06-25 · Exercise / conversion · Disposed 11,111 · Balance 0 F3: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.32 · Expires 2026-07-26 | Direct | 0 |
Reported balance
After 2021-06-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-06-25 · Exercise / conversion · Disposed 10,297 · Balance 0 F3: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $33.19 to $33.57, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnotes.
F2: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $33.29 to $33.78, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnotes.
F3: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 23, 2026 00:06 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 11,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-029340 · form4.xml · nonDerivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,322 F1 · shares: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 22:06 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 17,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026455 · form4.xml · nonDerivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,435 F1 · shares: The acquisition of 17,675 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 17,675 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 21:18 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 20,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-033628 · form4.xml · nonDerivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,760 F1 · shares: The acquisition of 20,541 shares of common stock of AngioDynamics, Inc.("AngioDynamics") represents 20,541 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant. Read SEC document |
| July 19, 2023 Filed Jul 22, 2023 01:11 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 17,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-035719 · form4.xml · nonDerivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,219 F1 · shares: The acquisition of 17,041 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 17,041 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 22:18 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 7,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-014361 · doc1.xml · nonDerivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,178 F1 · shares: The acquisition of 7,060 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,060 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/20/2023. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 22:45 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 5,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013921 · doc1.xml · nonDerivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,118 F1 · shares: The acquisition of 5,738 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 5,738 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/21/2022. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 21:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,297 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001562180-21-004531 · primarydocument.xml · derivative · entry 6 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,297 shares Expires 2026-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 21:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,111 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001562180-21-004531 · primarydocument.xml · derivative · entry 5 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,111 shares Expires 2025-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 21:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 10,297 | $33.48 | $344,714.73 |
DisclosureSEC source: 0001562180-21-004531 · primarydocument.xml · nonDerivative · entry 4 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,797 F2 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $33.29 to $33.78, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnotes. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 21:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 11,111 | $33.33 | $370,300.74 |
DisclosureSEC source: 0001562180-21-004531 · primarydocument.xml · nonDerivative · entry 3 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,094 F1 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $33.19 to $33.57, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnotes. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 21:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionCommon Stock | 11,111 | $4.32 | $47,999.52 |
DisclosureSEC source: 0001562180-21-004531 · primarydocument.xml · nonDerivative · entry 2 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 21:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionCommon Stock | 10,297 | $4.32 | $44,483.04 |
DisclosureSEC source: 0001562180-21-004531 · primarydocument.xml · nonDerivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 23:17 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 15,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013369 · doc1.xml · nonDerivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,380 F1 · shares: The acquisition of 15,323 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 15,323 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/14/2021. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:24 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 8,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004586 · primarydocument.xml · nonDerivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,797 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will be vesting 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 8,797 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 01:44 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 7,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-015055 · doc1.xml · nonDerivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,057 F1 · shares: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 22:37 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantStock Options (Right to buy) · Derivative | 15,741 | $0.00 Strike: $17.72 | $0.00 |
DisclosureSEC source: 0001562180-19-003568 · primarydocument.xml · derivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,741 Underlying: Common Stock · 15,741 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares subject to the option will vest in a series of 12 equal monthly increments over the one-year period following the Vesting Commencement Date, such that the option will be fully vested on the first anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Issuer's Board of Directors on each such applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.